Treatment of Superficial Bladder Cancer: A Discussion on Intravesical Immunotherapy and Intravesical Chemotherapy
- 31 March 2004
- journal article
- Published by Elsevier in European Urology Supplements
- Vol. 3 (3) , 70-72
- https://doi.org/10.1016/j.eursup.2004.02.012
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, 2002
- A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder CancerJournal of Urology, 1996
- Factors affecting recurrence and progression in superficial bladder tumoursEuropean Journal Of Cancer, 1995
- Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial.Journal of Clinical Oncology, 1995
- Apparent Failure of Current Intravesical Chemotherapy Prophylaxis to Influence the Long-Term Course of Superficial Transitional Cell Carcinoma of the BladderJournal of Urology, 1995
- A Prospective European Organization for Research and Treatment of Cancer Genitourinary Group Randomized Trial Comparing Transurethral Resection Followed by a Single Intravesical Instillation of Epirubicin or Water in Single Stage Ta, T1 Papillary Carcinoma of the BladderJournal of Urology, 1993
- Adjuvant Intravesicular Pharmacotherapy for Superficial Bladder CancerJNCI Journal of the National Cancer Institute, 1991
- Complications of Bacillus Calmette-Guerin Immunotherapy in 1,278 Patients with Bladder CancerJournal of Urology, 1986
- Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder TumorsJournal of Urology, 1976